Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework

11 Sept 2018

Abstract excerpt

In this diagnostic test validation study, we assessed the clinical accuracy and HPV genotyping performance of the INNO-LiPA HPV Genotyping Extra II (INNO-LiPA) within the VALGENT-3 framework. VALGENT is designed to assess the analytical and clinical performance of HPV tests with genotyping capacity. The VALGENT-3 panel comprised 1300 consecutive cervical cell specimens enriched with 300 samples with abnormal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervical Cancer and HPV Research
Share to Molecular Biology Techniques and Applications
Share to Reproductive tract infections research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30208597
DOI: 10.3390/ijms19092704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT FrameworkPMID 30208597Read ↗

Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.Semantic proximity Read ↗

Comparison of INNO-LiPA genotyping extra and hybrid capture 2 assays for detection of carcinogenic human papillomavirus genotypes.Semantic proximity Read ↗

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.Semantic proximity Read ↗

Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.Semantic proximity Read ↗

Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.Semantic proximity Read ↗

Performance of the New INNO-LiPA HPV extra to genotype human papillomavirus in cervical cell specimens.Semantic proximity Read ↗

Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.Semantic proximity Read ↗

Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.Semantic proximity Read ↗

Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.